Evaluation of the safety and efficacy of Advax(TM) as an adjuvant: A systematic review and meta-analysis

Akin I., Akdas S., Ceylan M. N., Altiner S., ARIBAL AYRAL P., YAZIHAN N.

ADVANCES IN MEDICAL SCIENCES, cilt.67, sa.1, ss.10-17, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 67 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.advms.2021.09.002
  • Dergi Adı: ADVANCES IN MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Food Science & Technology Abstracts, MEDLINE
  • Sayfa Sayıları: ss.10-17
  • Anahtar Kelimeler: Delta inulin, Systematic review, meta-Analysis, Advax(TM), MEMORY B-CELLS, NF-KAPPA-B, DELTA INULIN, INFLUENZA VACCINE, PROTECTION, ENCEPHALITIS, IMMUNOGENICITY, IMMUNIZATION, ANTIBODY, ANTIGEN
  • Ankara Üniversitesi Adresli: Evet

Özet

Purpose: Developing a vaccine with improved immunogenicity is still a growing priority for many diseases. Different types of adjuvants may be beneficial to initiate and maintain the long-lasting immunogenicity of vaccines. Evidence has shown that polysaccharide adjuvants are efficient in improving immunological mechanisms with their biocompatibility and biodegradability characteristics. In this study, we aimed to investigate the safety and efficacy of AdvaxTM an adjuvant derived from delta inulin. Methods: A systematic research was performed in Pubmed, Web of Science, and Scopus databases for the following keywords; "AdvaxTM" OR "delta inulin" until December 14th, 2020. RevMan 5.4.1 software was used for cumulative meta-analysis and bias analysis. We also used GraphPad Prism 6 software for the figures. Results: In the cumulative meta-analysis, it was found that seroconversion and geometric mean titers (GMT) levels significantly increased in AdvaxTM-adjuvanted group (mean difference: 12.31, 95% Cl [4.14, 20.47], p = 0.003; 17.10, 95% Cl [4.35, 29.85], p = 0.009, respectively). We also observed that AdvaxTM could be effective in improving immunogenicity by inducing T-cell responses and plasmablast generation in viral vaccines. Conclusions: In this study, it was shown that AdvaxTM is a safe and well-tolerated adjuvant. AdvaxTM could be a potent adjuvant in increasing the protection and immunogenicity of different vaccines without safety issues. However, further studies are needed to verify these effects of AdvaxTM adjuvant.